As tuberculosis (TB) rates continue to ascend the charts globally, molecular diagnostic firm QIAGEN has embarked on an ambitious strategy to bolster TB management and control with the launch of their innovative QIAseq xHYB Mycobacterium tuberculosis Panel. Primarily designed for research purposes, this panel prominently simplifies the process of culture-free whole genome sequencing from complex samples.
The new QIAseq panel’s suite of advanced features is set to offer remarkable benefits in several important areas. These include swift tracking of TB outbreaks, detecting and managing antimicrobial resistance - a critical paradigm of TB surveillance and control. The development of this panel is testament to the company’s commitment to accelerating TB research in a world where the disease’s threat looms large. QIAGEN’s initiative is an expansion on the strides made by the diagnostics test QuantiFERON-TB Gold Plus, which has carved its niche as a leading tool in TB diagnostics.
Simultaneously, QIAGEN is demonstrating its commitment to advancing cancer research. Showcased at the AACR Annual Meeting 2024, QIAGEN’s latest product inclusions display both groundbreaking results and product design. The novel QIAcuity dPCR PanCancer Kits embody a revolution in detection by identifying rare mutations of both EGFR and BRAF genes concurrently, thereby optimising time, cost, and material. Amplifying its cancer research portfolio, the company has also introduced a new QIAseq Targeted RNA-seq Panel tailored for T-cell Receptor. This variant assures the execution of targeted next-generation sequencing increasing both accuracy and sensitivity, proving to be a substantial leap in cancer studies.
Illustrating a commitment to non-invasive methods, QIAGEN’s PAXgene Urine Liquid Biopsy Set permits sample collection and cell-free DNA stabilization, thus unlocking further advancements in urine liquid biopsy and standing as proof of the company’s profound dedication to making future treatment more patient-friendly.
As QIAGEN continues to forge ahead in the arenas of medical research and diagnostics, sustainability is promoted at the heart of its operations. The company has recently earned the ACT Label for their new, eco-friendlier QIAwave products, recognising their lower environmental impact. This is accompanied by the My Green Lab Platinum certification achieved by QIAGEN’s Sample technologies R&D lab in Germany.
With a clear roadmap for achieving further certifications and a stern commitment to decrease plastic packaging and greenhouse gas emissions, QIAGEN truly manifests its dedication to Environmental, Social, and Governance strategy. Among their promising endeavors, strides towards enhancing their societal impact, with eco-friendly products and sustainable research methodologies unequivocally stands out. This synergy of innovation and sustainability marks a promising chapter for QIAGEN, TB management and control, as well as the whole landscape of cancer research.
Comments